etherna develops mRNA and lipid nanoparticle solutions.
etherna immunotherapies has raised $38.9M in total funding. The most recent round was Series B. The last funding was announced in August 2022.
etherna immunotherapies's investors include Omega Funds, EQT Life Sciences, Boehringer Ingelheim Venture Fund, European Commission, Novalis LifeSciences.
etherna immunotherapies is headquartered in Niel, Belgium.
etherna develops mRNA and lipid nanoparticle solutions.
etherna immunotherapies is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"etherna immunotherapies — Funding & Investors." VCBacked, August 23, 2022, https://www.vcbacked.co/company/etherna-immunotherapies. Accessed November 14, 2026.
VCBacked. (2022). etherna immunotherapies — Funding & Investors. Retrieved November 14, 2026, from https://www.vcbacked.co/company/etherna-immunotherapies
{{cite web |title=etherna immunotherapies — Funding & Investors |url=https://www.vcbacked.co/company/etherna-immunotherapies |website=VCBacked |access-date=November 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at etherna immunotherapies? Request a listing update